I did a comparision of the two trials in a different thread which ill copy below:
Lets do a comparison of Ruxolitnib vs Remestemcel-L trials:
Trial:Day 28 ORR:
- Single arm open label 49 patients
- Single arm open label 54 patients (Study 001)
Day 180 Survival:
- 40.7%-44.4% on grade 3-4 (grade c-d)
- 61%-67% on grade 3-4 (grade c-d)
Safety:
- 51% (n=25)
- 69% (n=37)
FDA Decision
- Multiple safety concerns/side effects including infections, sepsis, uti's, thrombosis and animia (adverse events lead to 31% of patients discontinuing treatment)
- No safety concerns identified with a safety profile similar to placebo (adverse events lead to 15% of patients discontinuing treatment)
- Approved
- ODAC voted 9-1 in favour of efficacy however FDA issued a CRL recommending a further trial to establish efficacy and to provide more scientific rationale to demonstrate potency relationships
Ruxolitnib has had a previous trial for the treatment of myelofibrosis. The trial results clearly show that from the available data, Remestemcel-L is a superior treatment with a much better safety profile.
Could msb argue that if the COVID-19 trial is successful this would provide sufficient evidence of relevant efficacy and safety similar to Ruxolitnib extension from myelofibrosis to GvHD based on the 1 single arm trial above?
- Forums
- ASX - By Stock
- MSB
- Ruxolitinib vs Ryoncil
MSB
mesoblast limited
Add to My Watchlist
7.55%
!
$1.78

Ruxolitinib vs Ryoncil, page-3
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.78 |
Change
0.125(7.55%) |
Mkt cap ! $2.258B |
Open | High | Low | Value | Volume |
$1.66 | $1.80 | $1.65 | $8.227M | 4.756M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
20 | 31663 | $1.78 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.79 | 4668 | 8 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
16 | 25235 | 1.780 |
12 | 65117 | 1.775 |
8 | 25629 | 1.770 |
11 | 52174 | 1.765 |
9 | 24329 | 1.760 |
Price($) | Vol. | No. |
---|---|---|
1.785 | 20665 | 14 |
1.790 | 24122 | 16 |
1.795 | 52692 | 7 |
1.800 | 422480 | 22 |
1.805 | 41550 | 7 |
Last trade - 13.31pm 01/07/2025 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Dr. Steven Gourlay, CEO
Dr. Steven Gourlay
CEO
Previous Video
Next Video
SPONSORED BY The Market Online